YOCSEF - 中国计算机学会
江苏省计算机学会
CCF业务总部&学术交流中心 - 中国计算机学会
智云研——全国高校算力服务平台
淮北计算机学会,小书圣,AI,头条,论坛,热搜,健康,养老,机器人,书法,亮点,生态,创新,动态,探索,数字化
计算机学会融创未来赛事平台
首页 - 乌鲁木齐金维图文信息科技有限公司 - Powered By 金维软件
青少年人工智能教育安阳服务中心-安阳C++信息学竞赛培训,青少年编程培训、机器人培训,让孩子轻松掌握编程技能
济南计算机学会-济南计算机学会
广西智慧称重科技有限公司www.智慧称重.cn,创于2006年,是高新技术企业,守合同重信用企业,中国衡器协会公路自动衡器专委会委员,广西人工智能学会/计算机学会/电子学会/公路学会理事…通过ISO9001、ISO14001和ISO45001体系认证,以工匠精神研制各类称重产品及软件系统,在华南尤其是广西衡器地磅市场致力于高端称重及自动称重控制系统的研发推广,现货供应无人值守地磅及汽车衡自助终端一体机、称重传感器、称重仪表、称重管理系统软件、梅特勒-托利多称重替代解决方案……
陕西省计算机学会―陕西省科协直属的省一级学会
哈尔滨市计算机学会哈尔滨市人工智能学会 - 哈尔滨市计算机学会哈尔滨市人工智能学会
WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity,foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.